The Development of Differentiation Agents for the Treatment of Prostate Cancer

Seminars in Oncology

Volumn 30, Issue 5, 2003, Pages 689-697

  Galsky, Matt ^b   Kelly, W Kevin ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; ARYLBUTYRIC ACID DERIVATIVE; AZACITIDINE; CALCITRIOL; CYCLINE; CYPROTERONE ACETATE; DEXAMETHASONE; DOXERCALCIFEROL; FENRETINIDE; GLUCOCORTICOID RECEPTOR; HISTONE DEACETYLASE INHIBITOR; LIAROZOLE; PACLITAXEL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN BCL 2; PROTEIN P53; RETINOIC ACID; RETINOID; RETINOID X RECEPTOR; ROSIGLITAZONE; TROGLITAZONE; UNINDEXED DRUG; VITAMIN D; VORINOSTAT; ZOLEDRONIC ACID;

APOPTOSIS; CASTRATION; CELL DIFFERENTIATION; CHEILITIS; CLINICAL TRIAL; CONFUSION; CONJUNCTIVITIS; DNA RESPONSIVE ELEMENT; HUMAN; HYPERCALCEMIA; KIDNEY FAILURE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SOMNOLENCE; TRANSCRIPTION REGULATION; XERODERMA PIGMENTOSUM;

EID: 0142062880     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(03)00355-5     Document Type: Article

References (62)

1. Huang ME, Ye YC, Chen SR, et al: Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72:567-572, 1988
2. Scher HI, Heller G: Clinical states in prostate cancer: Toward a dynamic model of disease progression. Urology 55: 323-327, 2000
3. LaTulippe E, Satagopan J, Smith A, et al: Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 62:4499-4506, 2002
4. Altucci L, Gronemeyer H: The promise of retinoids to fight against cancer. Nat Rev Cancer 1:181-193, 2001
5. Kelloff GJ, Lieberman R, Steele VE, et al: Chemoprevention of prostate cancer: Concepts and strategies. Eur Urol 35:342-350, 1999
6. Feldman D, Zhao XY, Krishnan AV: Vitamin D and prostate cancer. Endocrinology 141:5-9, 2000
7. Aranda A, Pascual A: Nuclear hormone receptors and gene expression. Physiol Rev 81:1269-1304, 2001
8. Talhnan MS, Andersen JW, Schiffer CA, et al: All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 337:1021-1028, 1997
9. Meyskens FL Jr, Surwit E, Moon TE, et al: Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: A randomized trial. J Natl Cancer Inst 86:539-543, 1994
10. Hong WK, Lippman SM, Itri LM, et al: Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 323:795-801, 1990
11. Peck GL: Topical tretinoin in actinic keratosis and basal cell carcinoma. J Am Acad Dermatol 15:829-835, 1986
12. Reichman ME, Hayes RB, Ziegler RG, et al: Serum vitamin A and subsequent development of prostate cancer in the first National Health and Nutrition Examination Survey Epidemiologic Follow-up Study. Cancer Res 50:2311-2315, 1990
13. Dahiya R, Park HD, Cusick J, et al: Inhibition of tumorigenic potential and prostate-specific antigen expression in LNCaP human prostate cancer cell line by 13-cis-retinoic acid. Int J Cancer 59:126-132, 1994
14. Pollard M, Luckert PH, Sporn MB: Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxy-phenyl)retinamide. Cancer Res 51:3610-3611, 1991
15. Pienta KJ, Nguyen NM, Lehr JE: Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide. Cancer Res 53:224-226, 1993
16. Kelly WK, Osman I, Reuter VE, et al: The development of biologic end points in patients treated with differentiation agents: An experience of retinoids in prostate cancer. Clin Cancer Res 6:838-846, 2000
17. Trump DL, Smith DC, Stiff D, et al: A phase II trial of all-trans-retinoic acid in hormone-refractory prostate cancer: A clinical trial with detailed pharmacokinetic analysis. Cancer Chemother Pharmacol 39:349-356, 1997
18. Culine S, Kramar A, Droz JP, et al: Phase II study of all-trans retinoic acid administered intermittently for hormone refractory prostate cancer. J Urol 161:173-175, 1999
19. Muindi JR, Young CW, Warrell RP Jr: Clinical pharmacology of all-trans retinoic acid. Leukemia 8:1807-1812, 1994
20. Muindi J, Frankel SR, Miller WH Jr, et al: Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: Implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia. Blood 79:299-303, 1992
21. Rigas JR, Francis PA, Muindi JR, et al: Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole. J Natl Cancer Inst 85:1921-1926, 1993
22. Adedoyin A, Stiff DD, Smith DC, et al: All-trans-retinoic acid modulation of drug-metabolizing enzyme activities: Investigation with selective metabolic drug probes. Cancer Chemother Pharmacol 41:133-139, 1998
23. Jung LL, Zamboni WC, Frye RF, et al: Modulation of all-trans-retinoic acid (ATRA) disposition with ketoconazole and disulfiram in patients with hormone-refractory prostate cancer. Proc Am Soc Clin Oncol 20:112a, 2001 (abstr 446)
24. Debruyne FJ, Murray R, Fradet Y, et al: Liarozole Study Group: Liarozole - A novel treatment approach for advanced prostate cancer: Results of a large randomized trial versus cyproterone acetate. Urology 52:72-81, 1998
25. Majewski S, Szmurlo A, Marczak M, et al: Synergistic effect of retinoids and interferon alpha on tumor-induced angiogenesis: Anti-angiogenic effect on HPV-harboring tumor-cell lines. Int J Cancer 57:81-85, 1994
26. Smith MA, Parkinson DR, Cheson BD, et al: Retinoids in cancer therapy. J Clin Oncol 10:839-864, 1992
27. Shalev M, Thompson TC, Frolov A, et al: Effect of 13-cis-retinoic acid on serum prostate-specific antigen levels in patients with recurrent prostate cancer after radical prostatectomy. Clin Cancer Res 6:3845-3849, 2000
28. Ferrari AC, Stone N, Stock R, et al: 13-Cis retinoic acid and complete androgen blockade in advanced hormone-naive prostate cancer patients: Report of a phase II randomized study. J Clin Oncol 20:538-544, 2002
29. DiPaola RS, Weiss RE, Cummings KB, et al: Effect of 13-cis-retinoic acid and alpha-interferon on transforming growth factor beta1 in patients with rising prostate-specific antigen. Clin Cancer Res 3:1999-2004, 1997
30. Goodin S, Rafi M, Cohen S, et al: A phase II trial of 13-cis-retinoic acid, alpha-interferon, and paclitaxel in patients with advanced prostate cancer. Proc Am Soc Clin Oncol 19:359a, 2000 (abstr)
31. Schwartz GG, Hulka BS: Is vitamin D deficiency a risk factor for prostate cancer? (hypothesis). Anticancer Res 10: 1307-1311, 1990
32. Corder EH, Guess HA, Hulka BS, et al: Vitamin D and prostate cancer: A prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 2:467-472, 1993
33. Osborn JL, Schwartz GG, Smith DC, et al: Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. Urol Oncol I:195-198, 1995
34. Gross C, Stamey T, Hancock S, et al: Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol 159:2035-2039, 1998
35. Trump DL, Serafine S, Brufsky A, et al: High dose calcitriol (1,25(OH)2 vitamin D3) + dexamethasone in androgen independent prostate cancer. Proc Am Soc Clin Oncol 19:337a, 2000 (abstr 1327)
36. Solit DB, Smaletz O, DeLaCruz A, et al: Phase I study of high dose calcitriol (1.25(OH)2) vitamin D3) and zoledronic acid in patients with prostate cancer. Proc Am Soc Clin Oncol 21:195a, 2002 (abstr 777)
37. Liu G, Oettel K, Ripple G, et al: Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer. Clin Cancer Res 8:2820-2827, 2002
38. Hershberger PA, Yu WD, Modzelewski RA, et al: Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res 7:1043-1051, 2001
39. Berman CL, Glode M, Crawford ED, et al: Vitamin D, dexamethasone, and carboplatin for hormone refractory prostate cancer, a phase II study. Proc Am Soc Clin Oncol 21:160b, 2002 (abstr 2455)
40. Beer TM, Eilers KM, Garzotto M, et al: Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 21:123-128, 2003
41. Marks P, Rifkind RA, Richon VM, et al: Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer 1:194-202, 2001
42. Marks PA, Richon VM, Rifkind RA: Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92:1210-1216, 2000
43. Van Lint C, Emiliani S, Verdin E: The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr 5:245-253, 1996
44. Archer SY, Meng S, Shei A, et al: p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci USA 95:6791-6796, 1998
45. Butler LM, Agus DB, Scher HI, et al: Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60:5165-5170, 2000
46. Butler LM, Webb Y, Agus DB, et al: Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin Cancer Res 7:962-970, 2001
47. Sandor V, Robbins AR, Robey R, et al: FR901228 causes mitotic arrest but does not alter microtubule polymerization. Anticancer Drugs 11:445-454, 2000
48. Walls R, Thibault A, Liu L, et al: The differentiating agent phenylacetate increases prostate-specific antigen production by prostate cancer cells. Prostate 29:177-182, 1996
49. Gilbert J, Baker SD, Bowling MK, et al: A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 7:2292-2300, 2001
50. Kelly WK, Richon VM, Troso-Sandoval T, et al: Suberoylanilide hydoxamic acid (SAHA), a histone deacetylase inhibitor: Biologic activity without toxicity. Proc Am Soc Clin Oncol 20:87a, 2001 (abstr 344)
51. Kelly WK, O'Connor O, Richon VM, et al: Phase I clinical trial of an oral formulation of the histone deacetylase inhibitor: Suberoylanilide hydroxamic acid (SAHA). Four-teenth EORTC-NCI-AACR Symposium on Molecular Targets and Cancer, Frankfurt, Germany, November 19-22, 2002
52. Gilbert J, Baker SD, Donehower RC, et al: Methyltransferase (MT) activity and gene expression in tumor biopsies from patients enrolled in a phase I study of the MT inhibitor, 5-azacytidine, and the histone deacetylase inhibitor, phenylbutyrate, in refractory solid tumors. Proc Am Soc Clin Oncol 20:87a, 2001 (abstr 344)
53. Tontonoz P, Hu E, Spiegelman BM: Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 79:1147-1156, 1994
54. Sarraf P, Mueller E, Jones D, et al: Differentiation and reversal of malignant changes in colon cancer through PPAR-gamma. Nat Med 4:1046-1052, 1998
55. Mueller E, Smith M, Sarraf P, et al: Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci USA 97:10990-10995, 2000
56. Kroll TG, Sarraf P, Pecciarini L, et al: PAX8-PPAR-gamma1 fusion oncogene in human thyroid carcinoma. Science 289:1357-1360, 2000
57. Kubota T, Koshizuka K, Williamson EA, et al: Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 58:3344-3352, 1998
58. Rosner GL, Stadler W, Ratain MJ: Randomized discontinuation design: Application to cytostatic antineoplastic agents. J Clin Oncol 20:4478-4484, 2002
59. Scher HI, Heller G: Picking the winners in a sea of plenty. Clin Cancer Res 8:400-404, 2002
60. Bowling MK, Nelson JB, Tong KP, et al: Biomarker responses in men with advanced prostate cancer (PCA) to infusional phenylbutyrate (PB). Proc Am Soc Clin Oncol 15:94, 1996 (abstr 43)
61. Urban D, Myers R, Manne U, et al: Evaluation of biomarker modulation by fenretinide in prostate cancer patients. Eur Urol 35:429-438, 1999
62. Lotan Y, Xu XC, Shalev M, et al: Differential expression of nuclear retinoid receptors in normal and malignant prostates. J Clin Oncol 18:116-121, 2000